

Regimen Reference Order – GENU – avelumab

ARIA: GENU - [avelumab]

Planned Course: Every 14 days until disease progression or unacceptable toxicity

Indication for Use: Urothelial Carcinoma; Metastatic or Locally Advanced; Maintenance

Drug Alert: Immune Checkpoint Inhibitor

CVAD: At Provider’s Discretion

Proceed with treatment if:

- *ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$*
- *AST/ALT less than 3 times the upper limit of normal*
- *Total bilirubin less than 1.5 times the upper limit of normal*
- *Creatinine clearance greater than 30 mL/minute*
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GENU – avelumab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
cetirizine*	10 mg	Orally 30 minutes prior to avelumab
acetaminophen*	650 mg	Orally 30 minutes prior to avelumab
avelumab	10 mg/kg	IV in normal saline 250 mL over 60 minutes <i>Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter</i>

***Pre-medications should be given for the first 4 cycles and may be discontinued or modified thereafter**

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders
- TSH every other cycle
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Patient should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
 - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

ADDITIONAL INFORMATION

- avelumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated